Onalespib

small molecule

Identifier: CI-DRUG-00000420
Entity page: /drug/onalespib ↗
Edges: 42

Neighbours: 17 cancers2 genes10 trials
Drawn: 29 of 29 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Onalespib targets …TARGETS2 of 2
→ targets	HSP90AB1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	HSP90AA1	—	INHIBITOR	—	1	Curated	chembl

Onalespib investigated for …INVESTIGATED_FOR4 of 4
→ investigated for	Triple-Negative Breast Carcinomamolecular_subtype	unknown	1	Triple-Negative Breast Carcinoma	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	1	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	1	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	1	Neoplasm	1	Curated	chembl	graph →

Onalespib investigated for …INVESTIGATED_FOR4 of 4

→ investigated for

Triple-Negative Breast Carcinomamolecular_subtype

unknown

Triple-Negative Breast Carcinoma

Curated

Onalespib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 25show all (up to 200)
→ investigated in trials for	Solid Neoplasm 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Solid Neoplasm 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Solid Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Carcinoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Triple-Negative Breast Carcinomamolecular_subtype 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Triple-Negative Breast Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Anaplastic Large Cell Lymphoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Anaplastic Large Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cutaneous Melanoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cutaneous Melanoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Large B-Cell Lymphoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube High Grade Serous Adenocarcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube High Grade Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Serous Adenocarcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Hypopharyngeal Squamous Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hypopharyngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Laryngeal Squamous Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Laryngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Mantle Cell Lymphoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Mantle Cell Lymphoma	1	Observed	clinicaltrials	graph →

Onalespib studied in …STUDIED_INderived10 of 11show all (up to 200)
→ studied in	NCT02535338Phase 1/Phase 2 · completed Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer · 11 trials list this drug (0 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02381535Phase 1 · completed Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin · 11 trials list this drug (0 active)	—	—	Laryngeal Squamous Cell Carcinoma,Hypopharyngeal Squamous Cell Carcinoma,Oropharyngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02503709Phase 1 · completed Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery · 11 trials list this drug (0 active)	—	—	Solid Neoplasm,Malignant Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02097225Phase 1 · terminated Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery · 11 trials list this drug (0 active)	—	—	Solid Neoplasm,Malignant Solid Neoplasm,Melanoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT00878423Phase 1 · completed Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors · 11 trials list this drug (0 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01685268Phase 1/Phase 2 · completed A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate · 11 trials list this drug (0 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01712217Phase 1/Phase 2 · completed A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib · 11 trials list this drug (0 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02898207Phase 1 · completed Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer · 11 trials list this drug (0 active)	—	—	Malignant Solid Neoplasm,Breast Carcinoma,Platinum-Resistant Primary Peritoneal Carcinoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT02474173Phase 1 · terminated Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer · 11 trials list this drug (0 active)	—	—	Malignant Breast Neoplasm,Breast Carcinoma,Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02572453Phase 2 · terminated Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL · 11 trials list this drug (0 active)	—	—	Anaplastic Large Cell Lymphoma,Transformed Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma+1	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths